TDF and TAF inhibit liver cancer cell migration, invasion via p7TP3
Abstract Tenofovir disoproxil fumarate (TDF) seems to prevent hepatocellular carcinoma (HCC) in patients with chronic hepatitis B virus (HBV). However, the mechanism is still little known. This study aimed to investigate the the roles and mechanisms of TDF, tenofovir alafenamide fumarate (TAF), and...
Main Authors: | Jing Zhao, Li Zhou, Yang Zhang, Jun Cheng, Yilan Zeng, Xiuling Li |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2024-04-01
|
Series: | Scientific Reports |
Subjects: | |
Online Access: | https://doi.org/10.1038/s41598-024-58807-z |
Similar Items
-
The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile
by: Squillace N, et al.
Published: (2020-12-01) -
Dynamics of Lipid Profile in Antiretroviral-Naïve HIV-Infected Patients, Treated with TAF-Based Regimens: A Multicenter Observational Study
by: Salvatore Martini, et al.
Published: (2022-12-01) -
Tribute to John C. Martin at the Twentieth Anniversary of the Breakthrough of Tenofovir in the Treatment of HIV Infections
by: Erik De Clercq
Published: (2021-12-01) -
Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide in patients with chronic hepatitis B: More questions than an answer
by: Pin-Nan Cheng, et al.
Published: (2024-04-01) -
Circ-CCT2 Activates Wnt/β-catenin Signaling to Facilitate Hepatoblastoma Development by Stabilizing PTBP1 mRNASummary
by: Qin Zhu, et al.
Published: (2024-01-01)